Abstract
In the 1990s, major improvements occurred in the therapeutic index of H1 antihistamines. The third-generation compounds promise to be more effective and nontoxic. The future major advances are likely to result from development and exploitation of non-H1 receptor-mediated antiallergic actions of these drugs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
